Search Result

Results for "

Hyperuricemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Apoptosis (6) Autophagy (1) Bacterial (2) Bcl-2 Family (2) Biochemical Assay Reagents (1) Caspase (2) COX (1) Cytochrome P450 (4) Dihydroorotate Dehydrogenase (1) Drug Derivative (1) Endogenous Metabolite (12) GLUT (5) HDAC (1) HSP (2) Interleukin Related (5) Isotope-Labeled Compounds (6) JNK (2) Keap1-Nrf2 (5) Lipoxygenase (1) MMP (3) mTOR (2) NF-κB (3) NO Synthase (1) OAT (2) Parasite (2) Reactive Oxygen Species (ROS) (4) Reference Standards (8) SOD (2) TGF-beta/Smad (3) Thrombin (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) TRP Channel (1) URAT1 (22) Xanthine Oxidase (45)
By Research Areas:	Cancer (14) Cardiovascular Disease (13) Endocrinology (1) Infection (10) Inflammation/Immunology (27) Metabolic Disease (64) Neurological Disease (5)

By Targets:

Antibiotic (2)

Apoptosis (6)

Autophagy (1)

Bacterial (2)

Bcl-2 Family (2)

Biochemical Assay Reagents (1)

Caspase (2)

COX (1)

Cytochrome P450 (4)

Dihydroorotate Dehydrogenase (1)

Drug Derivative (1)

Endogenous Metabolite (12)

GLUT (5)

HDAC (1)

HSP (2)

Interleukin Related (5)

Isotope-Labeled Compounds (6)

JNK (2)

Keap1-Nrf2 (5)

Lipoxygenase (1)

MMP (3)

mTOR (2)

NF-κB (3)

NO Synthase (1)

OAT (2)

Parasite (2)

Reactive Oxygen Species (ROS) (4)

Reference Standards (8)

SOD (2)

TGF-beta/Smad (3)

Thrombin (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

URAT1 (22)

Xanthine Oxidase (45)

By Research Areas:

Cancer (14)

Cardiovascular Disease (13)

Endocrinology (1)

Infection (10)

Inflammation/Immunology (27)

Metabolic Disease (64)

Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147300

Puliginurad YL-90148	URAT1	Cardiovascular Disease Metabolic Disease
Puliginurad (YL-90148) is a potent urate transporter (URAT) inhibitor. Puliginurad can be used for hyperuricemia and gout research .

HY-N9959

Isoengeletin	Others	Metabolic Disease Inflammation/Immunology
Isoengeletin is a flavonoid that can be isolated from the roots of Smilax bockii warb. Isoengeletin can be used as an active compound for the research of psoriasis, hyperuricemia and gout .

HY-19164

BOF-4272	Xanthine Oxidase	Metabolic Disease
BOF-4272 is a xanthine oxidase/xanthine dehydrogenase inhibitor. BOF-4272 can be used for hyperuricemia research .

HY-160265

URAT1 inhibitor 9	URAT1	Inflammation/Immunology
URAT1 inhibitor 9 (Compound 24) is an URAT1 inhibitor that can be used in the study of gout or hyperuricemia .

HY-174318

NARS-3′	Xanthine Oxidase	Metabolic Disease
NARS-3′ is an orally active reversible xanthine oxidase (XO) inhibitor with the IC₅₀ of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.

HY-144303

Xanthine oxidase-IN-4	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC₅₀ of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research .

HY-161523

XOR/URAT1-IN-1	Xanthine Oxidase URAT1	Metabolic Disease
XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC₅₀ of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model .

HY-151975

Xanthine oxidoreductase-IN-5	Xanthine Oxidase	Metabolic Disease
Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC₅₀ of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia .

HY-175309

URAT1-IN-14	URAT1	Metabolic Disease
URAT1-IN-14 is a potent and orally active Urate transporter 1 (URAT1) inhibitor. URAT1-IN-14 inhibits the human URAT1 in HEK293 cells with an IC₅₀ of 0.72 μM. URAT1-IN-14 exhibits low cytotoxic in Hep-G2 cells. URAT1-IN-14 shows urate-lowering effect in hyperuricemia mouse models. URAT1-IN-14 can be used for the study of hyperuricemia and gout .

HY-151973

Xanthine oxidoreductase-IN-3	Xanthine Oxidase	Metabolic Disease
Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC₅₀ of 26.3 nM. Xanthine oxidoreductase-IN-3 can be used for the research of acute hyperuricemia .

HY-W047156

Allantoxanamide	Biochemical Assay Reagents	Metabolic Disease
Allantoxanamide is a uricase inhibitor. Allantoxanamide-induced rats serve as animal models for studying purine biosynthesis, drug-induced hyperuricemia and hyperuricosuria, and related nephropathy .

HY-14268A

Febuxostat sodium TEI 6720 sodium; TMX 67 sodium	Xanthine Oxidase	Cardiovascular Disease Metabolic Disease Cancer
Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout .

HY-14268

Febuxostat Maximum Cited Publications 11 Publications Verification TEI 6720; TMX 67	Xanthine Oxidase	Cardiovascular Disease Metabolic Disease Cancer
Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-161514

Xanthine oxidase-IN-15	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-15 (Compound 6c) is a selective inhibitor of Xanthine oxidase (XO) (IC₅₀=0.13 μM). Xanthine oxidase-IN-15 inhibits XO catalysis by forming a stable interaction with the active site of XO. Xanthine oxidase-IN-15 is mainly used in the study of hyperuricemia and gout .

HY-162882

CC15009	Xanthine Oxidase Reactive Oxygen Species (ROS)	Metabolic Disease
CC15009 is a xanthine oxidoreductase (XOR) inhibitor, with an IC₅₀ value of 0.237 nM. CC15009 can inhibit the oxidative subtype of XOR, thereby reducing the production of the byproduct ROS and exhibiting antioxidant activity. CC15009 has demonstrated a good dose-dependent uric acid-lowering effect in two different mouse models of hyperuricemia induced by XOR substrates .

HY-14268R

Febuxostat (Standard) TEI 6720 (Standard); TMX 67 (Standard)	Reference Standards Xanthine Oxidase	Cardiovascular Disease Metabolic Disease
Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-158056

URAT1/GLUT9-IN-1	GLUT URAT1	Metabolic Disease
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC₅₀=2.01 μM) and glucose transporter 9 (GLUT9) (IC₅₀=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .

HY-146273

Xanthine oxidase-IN-7	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC₅₀ of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout .

HY-P2921B

Uricase, Arthrobacter globiformis Uox, Arthrobacter globiformis	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-P2921A

Uricase, Bacillus fastidious Uox, Bacillus fastidious	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-P2921C

Uricase (Recombinant) Uox (Recombinant)	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-N8309

Luteolin-4'-O-glucoside	Interleukin Related	Inflammation/Immunology Cancer
Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC₅₀ of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .

HY-139585

Tigulixostat LC350189	Xanthine Oxidase	Metabolic Disease
Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC₅₀ values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia .

HY-111345

Epaminurad UR-1102; URC-102	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research .

HY-14874

Topiroxostat 5+ Cited Publications FYX-051	Xanthine Oxidase Cytochrome P450	Metabolic Disease
Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC₅₀ value of 5.3 nM and a K_i value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .

HY-111345A

Epaminurad hydrochloride UR-1102 hydrochloride; URC-102 hydrochloride	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) hydrochloride is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research .

HY-14874R

Topiroxostat (Standard) FYX-051 (Standard)	Reference Standards Xanthine Oxidase Cytochrome P450	Metabolic Disease
Topiroxostat (Standard) is the analytical standard of Topiroxostat. This product is intended for research and analytical applications. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC₅₀ value of 5.3 nM and a K_i value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .

HY-N8309R

Luteolin-4'-O-glucoside (Standard)	Reference Standards Interleukin Related	Inflammation/Immunology Cancer
Luteolin-4'-O-glucoside (Standard) is the analytical standard of Luteolin-4'-O-glucoside. This product is intended for research and analytical applications. Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC₅₀ of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .

HY-Y0106

2,6-Dihydroxyacetophenone	mTOR Xanthine Oxidase Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-172774

TRPV1 antagonist 10	TRP Channel URAT1 GLUT Cytochrome P450 Interleukin Related TNF Receptor	Neurological Disease Inflammation/Immunology Endocrinology
TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC₅₀ = 33.06 nM), moderate to weak URAT1 (IC₅₀ = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain .

HY-153972

URAT1&XO inhibitor 2	URAT1 Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC₅₀ of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a K_i value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia .

HY-B0219A

Allopurinol sodium 5+ Cited Publications	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-B0219

Allopurinol 5+ Cited Publications	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-162910

HDAC-IN-79	Xanthine Oxidase HDAC Autophagy Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC₅₀=6.6 nM; HDAC1: IC₅₀=134 nM; HDAC2: IC₅₀=284 nM; HDAC3: IC₅₀=173 nM; HDAC6: IC₅₀=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC₅₀=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition .

HY-B0219R

Allopurinol (Standard)	Reference Standards Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-143906

URAT1 inhibitor 2	URAT1	Inflammation/Immunology
URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC₅₀ values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated ¹⁴C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .

HY-N8063R

γ-Glutamylornithine (Standard)	Endogenous Metabolite	Others
γ-Glutamylornithine is the urine excreta of patients with HHH syndrome (hyperuricemia, hyperaminemia, and hypercitrullinuria) and rotary atrophy associated with hyperuricemia. Increased levels of endogenous ornithine increase levels of γ-Glutamylornithine in the urine .

HY-N8063

γ-Glutamylornithine	Endogenous Metabolite	Others
γ-Glutamylornithine is the urine excreta of patients with HHH syndrome (hyperuricemia, hyperaminemia, and hypercitrullinuria) and rotary atrophy associated with hyperuricemia. Increased levels of endogenous ornithine increase levels of γ-Glutamylornithine in the urine .

HY-101439

JTT-552	URAT1	Others
JTT-552 is a compound targeting URAT1 with activity in inhibiting hyperuricemia and gout.

HY-W052011

Ruzinurad HR011303; SHR4640	URAT1	Metabolic Disease
Ruzinurad (HR011303) is a highly selective URATl inhibitor (WO2020088641, compound I). Ruzinurad can be used in the study of hyperuricemia .

HY-156624

Lingdolinurad	URAT1	Metabolic Disease
Lingdolinurad is urate transporter inhibitor, targeting to hURAT1.Lingdolinurad can be used for research in hyperuricemia in vitro and in vivo .

HY-157306

HC-1310	URAT1	Metabolic Disease
HC-1310 URAT1 Inhibitor (Compound 83) is a potent URAT1 inhibitor and can be used for research on hyperuricemia and gout .

HY-B0535

Ethambutol 2 Publications Verification	Bacterial Antibiotic	Infection
Ethambutol is an antimycobacterial compound that prevents cell wall formation by inhibiting arabinosyltransferase activity. Ethambutol can be used to establish animal models of hyperuricemia and optic neuropathy.

HY-B0535A

Ethambutol dihydrochloride 2 Publications Verification Emb dihydrochloride	Bacterial Antibiotic	Infection
Ethambutol dihydrochloride is an antimycobacterial compound that prevents cell wall formation by inhibiting arabinosyltransferase activity. Ethambutol dihydrochloride can be used to establish animal models of hyperuricemia and optic neuropathy.

HY-153706

URAT1 inhibitor 5	URAT1	Cardiovascular Disease Metabolic Disease
URAT1 inhibitor 5 (compound 16) is a potent URAT1 inhibitor. URAT1 inhibitor 5 can be used in research of hyperuricemia .

HY-153968

URAT1&XO inhibitor 1	Xanthine Oxidase URAT1	Metabolic Disease
URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC₅₀=~10 μM) and Xanthine Oxidase (IC₅₀=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research .

HY-14669

Niraxostat Y-700; Piraxostat	Xanthine Oxidase	Metabolic Disease
Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved .

HY-113048A

Erythronic acid potassium 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
Erythronic acid potassium is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-W104467

(+/-)-Epicatechin (+/-)-Epicatechol; (+/-)-epi-Catechin	Xanthine Oxidase	Metabolic Disease
(+/-)-Epicatechin is a xanthine oxidase inhibitor with an IC₅₀ of 982.14 μM, and can be found in Semen Plantaginis (Plantago seed). (+/-)-Epicatechin can be used in research on diseases such as hyperuricemia and gout .

HY-113048

Erythronic acid	Endogenous Metabolite	Metabolic Disease
Erythronic acid is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

Cat. No.	Product Name	Type

HY-W014841

Sodium hippurate, 98%

N-Benzoylglycine sodium, 98%

Microbial Culture

Sodium hippurate, 98% is an orally active metabolite. Sodium hippurate, 98% can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Sodium hippurate, 98% decreases NRF2, MMP9 and leads to ROS accumulation. Sodium hippurate, 98% activates TGFβ/SMAD signaling. Sodium hippurate, 98% improves hyperuricemia and colitis. Sodium hippurate, 98% can also be used in cardiovascular disease research . .

Cat. No.	Product Name	Target	Research Area

HY-P2813

Hirudin 2 Publications Verification	Thrombin Apoptosis	Cardiovascular Disease Cancer
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9959

Isoengeletin	Structural Classification Smilax biumbellata T. Koyama Flavonoids Smilacaceae Flavonones Source classification Plants	Others
Isoengeletin is a flavonoid that can be isolated from the roots of Smilax bockii warb. Isoengeletin can be used as an active compound for the research of psoriasis, hyperuricemia and gout .

HY-N8309

Luteolin-4'-O-glucoside	Punica granatum L. Classification of Application Fields Flavones Source classification Plants Biological Pesticide Research Agricultural Research Flavonoids Phenols Polyphenols Punicaceae Inflammation/Immunology Disease Research Fields Cancer	Interleukin Related
Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC₅₀ of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .

HY-Y0106

2,6-Dihydroxyacetophenone	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields	mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-N8063

γ-Glutamylornithine	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
γ-Glutamylornithine is the urine excreta of patients with HHH syndrome (hyperuricemia, hyperaminemia, and hypercitrullinuria) and rotary atrophy associated with hyperuricemia. Increased levels of endogenous ornithine increase levels of γ-Glutamylornithine in the urine .

HY-B0535A

Ethambutol dihydrochloride 2 Publications Verification Emb dihydrochloride	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Disease Research Fields	Bacterial Antibiotic
Ethambutol dihydrochloride is an antimycobacterial compound that prevents cell wall formation by inhibiting arabinosyltransferase activity. Ethambutol dihydrochloride can be used to establish animal models of hyperuricemia and optic neuropathy.

HY-113048A

Erythronic acid potassium 1 Publications Verification	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Monosaccharides	Endogenous Metabolite
Erythronic acid potassium is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-N8309R

Luteolin-4'-O-glucoside (Standard)	Flavonoids Punica granatum L. Flavones Source classification Phenols Polyphenols Punicaceae Plants	Reference Standards Interleukin Related
Luteolin-4'-O-glucoside (Standard) is the analytical standard of Luteolin-4'-O-glucoside. This product is intended for research and analytical applications. Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC₅₀ of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .

HY-N8063R

γ-Glutamylornithine (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
γ-Glutamylornithine is the urine excreta of patients with HHH syndrome (hyperuricemia, hyperaminemia, and hypercitrullinuria) and rotary atrophy associated with hyperuricemia. Increased levels of endogenous ornithine increase levels of γ-Glutamylornithine in the urine .

HY-W104467

(+/-)-Epicatechin (+/-)-Epicatechol; (+/-)-epi-Catechin	Malvaceae Structural Classification Flavonoids Flavanols Source classification Phenols Polyphenols Plants Scaphium wallichii	Xanthine Oxidase
(+/-)-Epicatechin is a xanthine oxidase inhibitor with an IC₅₀ of 982.14 μM, and can be found in Semen Plantaginis (Plantago seed). (+/-)-Epicatechin can be used in research on diseases such as hyperuricemia and gout .

HY-113048

Erythronic acid	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Monosaccharides	Endogenous Metabolite
Erythronic acid is an endogenous metabolite of carbohydrates that can be used in the study of metabolism-related diseases. It plays a key role in the onset and improvement of hyperuricemia and is related to mitochondrial dysfunction in transaldolase deficiency .

HY-N8761

Kihadanin A	Structural Classification Natural Products Dictamnus dasycarpus Turcz. Source classification Rutaceae Plants	NO Synthase
Kihadanin A (compound 3) is a limonoid NOS3 inhibitor that can be isolated from the methanol extract of Dictamnus dasycarpus root bark. Kihadanin A is useful in the study of hyperuricemia (HUA) [3].

HY-P2813

Hirudin 2 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Animals Classification of Application Fields Source classification Disease Research Fields Cancer	Thrombin Apoptosis
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

HY-N10433

Xanthine oxidase-IN-9 Icarisids E	Flavonoids Juglandaceae Source classification Cyclocarya paliurus (Batal.) Iljinsk. Plants	Xanthine Oxidase
Xanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC₅₀ of 31.81 μM .

HY-N9324

Ilexoside O	Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Inflammation/Immunology Tabernaemontana elegans Stapf	Xanthine Oxidase
Ilexoside O is a triterpene saponin isolated from the roots of Ilex pubescens. Ilexoside O exhibits weak xanthine oxidase (XOD) inhibitory activity (IC₅₀=53.05 μM) .

HY-W016562

Hippuric acid Benzoylglycine	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields	Endogenous Metabolite Keap1-Nrf2 MMP Reactive Oxygen Species (ROS) TGF-beta/Smad
Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research . .

HY-108844

Rasburicase	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Xanthine Oxidase
Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout .

HY-Y0106R

2,6-Dihydroxyacetophenone (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Endogenous metabolite	Reference Standards mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-W016562R

Hippuric acid (Standard) Benzoylglycine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite	Reference Standards Endogenous Metabolite
Hippuric acid (Standard) is the analytical standard of Hippuric acid. This product is intended for research and analytical applications. Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research . .

Cat. No.	Product Name	Chemical Structure

HY-B0219S

Allopurinol-d2
Allopurinol-d₂ is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC₅₀ values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect .

HY-14268S2

Febuxostat-d3
Febuxostat-d₃ (TEI 6720-d₃) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-14268S3

Febuxostat-d5
Febuxostat-d₅ (TEI 6720-d₅) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-14874S

Topiroxostat-d4
Topiroxostat-d₄ is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC₅₀ value of 5.3 nM and a K_i value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .

HY-W747703

Hippuric acid-13C6

Hippuric acid- ¹³C₆ (Benzoylglycine- ¹³C₆) is ¹³C labeled Hippuric acid. Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research . .

HY-B0219S1

Allopurinol-13C,15N2

Allopurinol- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled labeled Allopurinol (HY-B0219). Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks